Get Your Boom! Back AminoBoosters Sources and References
ISSN 0975-413X CODEN (USA): PCHHAX, Der Pharma Chemica, 2016, 8(18):127-131,

[1] Halim, D., Murti, H., Sandra, F., Boediono, A., Djuwantono, T., Setiawan, B. ( 2010). Stem Cell : Jakarta: PT.
Penerbit Erlangga.

[2] Abdulazeez, S., S. ( 2014). A rapid review of the current and future scope of stem cell research. Saudi
Pharmaceutical Journal, xxx, 8.

[3] Fodor, W.L. ( 2003). Tissue engineering and cell based therapies, from the bench to the clinic: Reproductive
Biology and Endocrinology 1, 6.

[4] Anonim. ( 2014). Retrieved November 15th, 2014

[5]Wild, S., Roglic, G., Green, A., Sicree, R., and King, H. ( 2004). Diabetes Care, 27, 6.

[6] Aditama, T.Y., Retrieved February 4th, 2005

[7] Nolan, J., K., Phillips, M., Mine, Y. ( 2005). J. Agric. Food Chem, 53(22), 10.

[8] Dharma S, Mimi A, Uci W, Dillasamola D, Research Journal of Pharmaceutical, Biological and Chemical
Sciences 7(5):481-487 · September 2016

[9] Thisse, B., Thisse, C. ( 2005). Dev Biol, 287, 12.

[10]Dharma S, Sanubari R, Jenny M, Dillasamola DMimi A, Uci W, Dillasamola D, Research Journal of
Pharmaceutical, Biological and Chemical Sciences 7(1):2059-2067 · January 2016

[11]Wheater PR, B.H., Daniels VG.. . ( 1979). .London : Lonh Grup Limited.

[12]Runiana, ( 2009). Institut Pertanian Bogor

[13] .P. Eswarakumar, I.L., J. Schlessinger. ( 2005). Cytokine & Growth Factor Reviews 16, 11

1. Study of YTE on stress: Effects of powdered fertilized eggs on the stress response

2. Study on YTE for antidepressant: A placebo controlled, double-blind study on the efficacy of a nutritive supplement containing embryonic peptides in treatment of mild to moderate depressive mood.

3. YTE for strength increase and hormone production: Effects of nutritional Supplements designed to promote lean tissue accretion on body composition and strength performance.

4. Effects of Protein Supplements on the natural Production of Hormones subsequent to hard Training. 1996/97

5. YTE for sexual desire: A randomized placebo-controlled study of “Libido” (YTE) on sexual lust in middle-aged, healthy men” 1992

6. A randomized placebo-controlled study of “Libido” (YTE) on sexual desire in healthy middle-aged men” 1993

7. “The Swedish Study” Sexual Desire in Men: Effects of Oral Ingestion of a Product Derived from Fertilized Eggs.

8. The Effect of “Libido” (YTE) on decreased sexual Desire associated with Anti-Depressant Medication. 1996/97

9. Effects of Fertilized incubated Shell Eggs on sexual Behavior of Male Rats 1996.
1. Allain H, Raoul P, Lieury A, LeCoz F, Gandon JM, D’Arbigny P. Effect of two doses of Gingko biloba extract (EGb 761) on the dual-coding test in elderly subjects. Clinical Therapeutics. 1993;15(3):549–558. [PubMed]

2. Itil T, Martorano D. Natural substances in psychiatry (Ginkgo biloba in dementia) Psychopharmacology Bulletin. 1995;31(1):147–158. [PubMed]

3. Kanowski S, Herrmann WM, Stephan K, Wierich W, Hörr R. Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry. 1996;29(2):47–56. [PubMed]

4. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. Journal of the American Medical Association. 1997;278(16):1327–1332. [PubMed]

5. Ramassamy C, Longpre F, Christen Y. Ginkgo biloba extract (EGb 761) in Alzheimer’s disease: is there any evidence? Current Alzheimer Research. 2007;4(3):253–262. [PubMed]

6. Zimmermann M, Colciaghi F, Cattabeni F, Di Luca M. Ginkgo biloba extract: from molecular mechanisms to the treatment of Alzhelmer’s disease. Cellular and Molecular Biology. 2002;48(6):613–623. [PubMed]

7. Elsabagh S, Hartley DE, Ali O, Williamson EM, File SE. Differential cognitive effects of Ginkgo biloba after acute and chronic treatment in healthy young volunteers. Psychopharmacology. 2005;179(2):437–446. [PubMed]

8. Gertz HJ, Kiefer M. Review about Ginkgo biloba special extract EGb 761 (Ginkgo) Current Pharmaceutical Design. 2004;10(3):261–264. [PubMed]

9. Kennedy DO, Jackson PA, Haskell CF, Scholey AB. Modulation of cognitive performance following single doses of 120 mg Ginkgo biloba extract administered to healthy young volunteers. Human Psychopharmacology. 2007;22(8):559–566. [PubMed]

10. Kennedy DO, Scholey AB, Wesnes KA. The dose-dependent cognitive effects of acute administration of Ginkgo biloba to healthy young volunteers. Psychopharmacology. 2000;151(4):416–423. [PubMed]

11. Kurz A, Van Baelen B. Ginkgo biloba compared with cholinesterase inhibitors in the treatment of dementia: a review based on meta-analyses by the cochrane collaboration. Dementia and Geriatric Cognitive Disorders. 2004;18(2):217–226. [PubMed]

12. Mazza M, Capuano A, Bria P, Mazza S. Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study. European Journal of Neurology. 2006;13(9):981–985. [PubMed]

13. Rigney U, Kimber S, Hindmarch I. The effects of acute doses of standardized Ginkgo biloba extract on memory and psychomotor performance in volunteers. Phytotherapy Research. 1999;13(5):408–415. [PubMed]

14. Scholey A, Kennedy D. Acute, dose-dependent cognitive effects of Ginkgo biloba, Panax ginseng and their combination in healthy young volunteers: differential interactions with cognitive demand. Human Psychopharmacology. 2002;17(1):35–44. [PubMed]

15. Stough C, Clarke J, Lloyd J, Nathan PJ. Neuropsychological changes after 30-day Ginkgo biloba administration in healthy participants. International Journal of Neuropsychopharmacology. 2001;4(2):131–134. [PubMed]

16. Subhan Z, Hindmarch I. The psychopharmacological effects of Ginkgo biloba extract in normal healthy volunteers. International Journal of Clinical Pharmacology Research. 1984;4(2):89–93. [PubMed]

17. Wesnes K, Simmons D, Rook M, Simpson P. A double-blind placebo-controlled trial of Tanakan in the treatment of idiopathic cognitive impairment in the elderly. Human Psychopharmacology. 1987;2:159–169.

18. Weinmann S, Roll S, Schwarzbach C, Vauth C, Willich SN. Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatrics. 2010;10 Article ID 14. [PMC free article] [PubMed]

19. DeKosky ST, Williamson JD, Fitzpatrick AL, et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. Journal of the American Medical Association. 2008;300(19):2253–2262. [PMC free article] [PubMed]

20. Andrieu S, Ousset PJ, Coley N, Ouzid M, Mathiex-Fortunet H, Vellas B. GuidAge study: a 5-year double blind, randomised trial of EGb 761 for the prevention of Alzheimer’s disease in elderly subjects with memory complaints. I. Rationale, design and baseline data. Current Alzheimer Research. 2008;5(4):406–415. [PubMed]

21. IPSEN. Encouraging results of GuidAge, large scale European trial conducted in the prevention of Alzheimer’s Dementia. 2010. 22 June.

22. Kaschel R. Ginkgo biloba: specificity of neuropsychological improvement—a selective review in search of differential effects. Human Psychopharmacology. 2009;24(5):345–370. [PubMed]

23. Kennedy DO, Scholey AB, Wesnes KA. Differential, dose dependent changes in cognitive performance following acute administration of a Ginkgo biloba/Panax ginseng combination to healthy young volunteers. Nutritional Neuroscience. 2001;4(5):399–412. [PubMed]

24. Polich J, Gloria R. Cognitive effects of a Ginkgo biloba/vinpocetine compound in normal adults: systematic assessment of perception, attention and memory. Human Psychopharmacology. 2001;16(5):409–416. [PubMed]

25. DeFeudis FV, Drieu K. Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Current Drug Targets. 2000;1(1):25–58. [PubMed]

26. Ahlemeyer B, Krieglstein J. Neuroprotective effects of Ginkgo biloba extract. Cellular and Molecular Life Sciences. 2003;60(9):1779–1792. [PubMed]

27. Nathan P. Can the cognitive enhancing effects of Ginkgo biloba be explained by its pharmacology? Medical Hypotheses. 2000;55(6):491–493. [PubMed]

28. Mahadevan S, Park Y. Multifaceted therapeutic benefits of Ginkgo biloba L.: chemistry, efficacy, safety, and uses. Journal of Food Science. 2008;73(1):R14–R19. [PubMed]

29. Krištofiková Z. In vitro effect of Ginkgo biloba extract (EGb 761) on the activity of presynaptic cholinergic nerve terminals in rat hippocampus. Dementia and Geriatric Cognitive Disorders. 1997;8(1):43–48. [PubMed]

30. Rendeiro C, Spencer JPE, Vauzour D, Butler LT, Ellis JA, Williams CM. The impact of flavonoids on spatial memory in rodents: from behaviour to underlying hippocampal mechanisms. Genes and Nutrition. 2009;4(4):251–270. [PMC free article] [PubMed]

31. Chopin P, Briley M. Effects of four non-cholinergic cognitive enhancers in comparison with tacrine and galanthamine on scopolamine-induced amnesia in rats. Psychopharmacology. 1992;106(1):26–30. [PubMed]

32. Taylor JE. Neuromediator binding to receptors in the rat brain. The effect of chronic administration of Ginkgo biloba extract. Presse Medicale. 1986;15:491–493. [PubMed]

33. Ellis KA, Nathan PJ. The pharmacology of human working memory. International Journal of Neuropsychopharmacology. 2001;4(3):299–313. [PubMed]

34. Furey ML, Pietrini P, Alexander GE, Schapiro MB, Horwitz B. Cholinergic enhancement improves performance on working memory by modulating the functional activity in distinct brain regions: a positron emission tomography regional cerebral blood flow study in healthy humans. Brain Research Bulletin. 2000;51(3):213–218. [PubMed]

35. Furey ML, Pietrini P, Haxby JV. Cholinergic enhancement and increased selectivity of perceptual processing during working memory. Science. 2000;290(5500):2315–2319. [PubMed]

36. Rombouts SARB, Barkhof F, Van Meel CS, Scheltens P. Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer’s disease. Journal of Neurology Neurosurgery and Psychiatry. 2002;73(6):665–671. [PMC free article] [PubMed]

37. Terry AV, Jackson WJ, Buccafusco JJ. Effects of concomitant cholinergic and adrenergic stimulation on learning and memory performance by young and aged monkeys. Cerebral Cortex. 1993;3(4):304–312. [PubMed]

38. Mori K, Yamashita H, Nagao M, Horiguchi J, Yamawaki S. Effects of anticholinergic drug withdrawal on memory, regional cerebral blood flow and extra-pyramidal side effects in schizophrenic patients. Pharmacopsychiatry. 2002;35(1):6–11. [PubMed]

39. Rusted JM. Dissociative effects of scopolamine on working memory in healthy young volunteers. Psychopharmacology. 1988;96(4):487–492. [PubMed]

40. Itil TM, Eralp E, Tsambis E, Itil KZ, Stein U. Central nervous system effects of Ginkgo biloba, a plant extract. American Journal of Therapeutics. 1996;3(1):63–73. [PubMed]

41. Kennedy DO, Scholey AB, Drewery L, Marsh VR, Moore B, Ashton H. Electroencephalograph effects of single doses of Ginkgo biloba and Panax ginseng in healthy young volunteers. Pharmacology Biochemistry and Behavior. 2003;75(3):701–709. [PubMed]

42. Hofferberth B. The efficacy of EGb 761 in patients with senile dementia of the Alzheimer type, a double-blind, placebo-controlled study on different levels of investigation. Human Psychopharmacology. 1994;9(3):215–222.

43. Klimesch W. EEG alpha and theta oscillations reflect cognitive and memory performance: a review and analysis. Brain Research Reviews. 1999;29(2-3):169–195. [PubMed]

44. Semlitsch HV, Anderer P, Saletu B, Binder GA, Decker KA. Cognitive psychophysiology in nootropic drug research: effects of Ginkgo biloba on event-related potentials (P300) in age-associated memory impairment. Pharmacopsychiatry. 1995;28(4):134–142. [PubMed]

45. Santos RF, Galduróz JCF, Barbieri A, Castiglioni MLV, Ytaya LY, Bueno OFA. Cognitive performance, SPECT, and blood viscosity in elderly non-demented people using Ginkgo biloba. Pharmacopsychiatry. 2003;36(4):127–133. [PubMed]

46. Timerbaeva SL, Suslina ZA, Bodareva EA, Fedin PA, Korepina OS, Pervozvansky BE. Tanakan in the treatment of primary manifestations of insufficiency of brain blood supply. Zhurnal Nevropatolgii i Psikhiatrii im. S S Korsakova. 2000;100(8):24–28. [PubMed]

47. Silberstein RB, Farrow M, Levy F, Pipingas A, Hay DA, Jarman FC. Functional brain electrical activity mapping in boys with attention- deficit/hyperactivity disorder. Archives of General Psychiatry. 1998;55(12):1105–1112. [PubMed]

48. Silberstein RB, Nunez PL, Pipingas A, Harris P, Danieli F. Steady state visually evoked potential (SSVEP) topography in a graded working memory task. International Journal of Psychophysiology. 2001;42(2):219–232. [PubMed]

49. Naghavi HR, Nyberg L. Common fronto-parietal activity in attention, memory, and consciousness: shared demands on integration? Consciousness and Cognition. 2005;14(2):390–425. [PubMed]

50. Wager TD, Smith EE. Neuroimaging studies of working memory: a meta-analysis. Cognitive, Affective and Behavioral Neuroscience. 2003;3(4):255–274. [PubMed]

51. Vanderplas JM, Garvin EA. The association value of random shapes. Journal of Experimental Psychology. 1959;57(3):147–154. [PubMed]

52. Silberstein RB, Schier MA, Pipingas A, Ciorciari J, Wood SR, Simpson DG. Steady-state visually evoked potential topography associated with a visual vigilance task. Brain Topography. 1990;3(2):337–347. [PubMed]

53. Silberstein RB. Steady-state visually evoked potentials, brain resonances, and cognitive processes. In: Nunez PL, editor. Neocortical Dynamics and Human EEG Rhythms. New York, NY, USA: Oxford University Press; 1995. pp. 272–303.

54. Silberstein RB, Ciorciari J, Pipingas A. Steady-state visually evoked potential topography during the Wisconsin card sorting test. Electroencephalography and Clinical Neurophysiology. 1995;96(1):24–35. [PubMed]

55. Regan D. Human Brain Electrophysiology: Evoked Potentials and Evoked Magnetic Fields in Science and Medicine. New York, NY, USA: Elsevier; 1989.

56. Gasser T, Sroka L, Mocks J. The transfer of EOG activity into the EEG for eyes open and closed. Electroencephalography and Clinical Neurophysiology. 1985;61(2):181–193. [PubMed]

57. Nunez PL, Silberstein RB, Cadusch PJ, Wijesinghe R. Comparison of high resolution EEG methods having different theoretical bases. Brain Topography. 1993;5(4):361–364. [PubMed]

58. Duffy FH, Bartels PH, Burchfiel JL. Significance probability mapping: an aid in the topographic analysis of brain electrical activity. Electroencephalography and Clinical Neurophysiology. 1981;51(5):455–462. [PubMed]

59. Harner RN. Topographic analysis of multichannel EEG data. In: Samson-Dollfus D, editor. Statistics and Topography in Quantitative EEG. New York, NY, USA: Elsevier; 1988. pp. 49–61.

60. Silberstein RB, Cadusch PJ. Measurement processes and spatial principal components analysis. Brain Topography. 1992;4(4):267–276. [PubMed]

61. Perlstein WM, Cole MA, Larson M, Kelly K, Seignourel P, Keil A. Steady-state visual evoked potentials reveal frontally-mediated working memory activity in humans. Neuroscience Letters. 2003;342(3):191–195. [PubMed]

62. Perlstein WM, Elbert T, Stenger VA. Dissociation in human prefrontal cortex of affective influences on working memory-related activity. Proceedings of the National Academy of Sciences of the United States of America. 2002;99(3):1736–1741. [PMC free article] [PubMed]

63. Jensen O, Gelfand J, Kounios J, Lisman JE. Oscillations in the alpha band (9-12 Hz) increase with memory load during retention in a short-term memory task. Cerebral Cortex. 2002;12(8):877–882. [PubMed]

64. Klimesch W, Doppelmayr M, Schwaiger J, Auinger P, Winkler TH. ‘Paradoxical‘ alpha synchronization in a memory task. Cognitive Brain Research. 1999;7(4):493–501. [PubMed]

65. Van Rooy C, Stough C, Pipingas A, Hocking C, Silberstein RB. Spatial working memory and intelligence biological correlates. Intelligence. 2001;29(4):275–292.

66. Pfurtscheller G, Lopes Da Silva FH. Event-related EEG/MEG synchronization and desynchronization: basic principles. Clinical Neurophysiology. 1999;110(11):1842–1857. [PubMed]

67. Itil TM, Eralp E, Ahmed I, Kunitz A, Itil KZ. The pharmacological effects of Ginkgo biloba, a plant extract, on the brain of dementia patients in comparison with tacrine. Psychopharmacology Bulletin. 1998;34(3):391–397. [PubMed]

68. Ebert U, Oertel R, Kirch W. Physostigmine reversal of midazolam-induced electroencephalographic changes in healthy subjects. Clinical Pharmacology and Therapeutics. 2000;67(5):538–548. [PubMed]

69. Sannita WG, Maggi L, Rosadini G. Effects of scopolamine (0.25-0.75 mg i.m.) on the Quantitative EEG and the neuropsychological status of healthy volunteers. Neuropsychobiology. 1987;17(4):199–205. [PubMed]

70. Thompson JC, Tzambazis K, Stough C, Nagata K, Silberstein RB. The effects of nicotine on the 13 Hz steady-state visually evoked potential. Clinical Neurophysiology. 2000;111(9):1589–1595. [PubMed]

71. Silberstein RB, Line P, Pipingas A, Copolov D, Harris P. Steady-state visually evoked potential topography during the continuous performance task in normal controls and schizophrenia. Clinical Neurophysiology. 2000;111(5):850–857. [PubMed]

72. Line P, Silberstein RB, Wright JJ, Copolov DL. Steady state visually evoked potential correlates of auditory hallucinations in schizophrenia. NeuroImage. 1998;8(4):370–376. [PubMed]

73. Wu M, Shanabrough M, Leranth C, Alreja M. Cholinergic excitation of septohippocampal GABA but not cholinergic neurons: implications for learning and memory. Journal of Neuroscience. 2000;20(10):3900–3908. [PubMed]

74. Klausberger T, Magill PJ, Márton LF, et al. Brain-state- and cell-type-specific firing of hippocampal interneurons in vivo. Nature. 2003;421(6925):844–848. [PubMed]

75. Rao SG, Williams GV, Goldman-Rakic PS. Destruction and creation of spatial tuning by disinhibition: GABA(A) blockade of prefrontal cortical neurons engaged by working memory. Journal of Neuroscience. 2000;20(1):485–494. [PubMed]

76. Varela F, Lachaux JP, Rodriguez E, Martinerie J. The brainweb: phase synchronization and large-scale integration. Nature Reviews Neuroscience. 2001;2(4):229–239. [PubMed]

77. Leventhal AG, Wang Y, Pu M, Zhou Y, Ma Y. GABA and its agonists improved visual cortical function in senescent monkeys. Science. 2003;300(5620):812–815. [PubMed]

78. Schmolesky MT, Wang Y, Pu M, Leventhal AG. Degradation of stimulus selectivity of visual cortical cells in senescent rhesus monkeys. Nature Neuroscience. 2000;3(4):384–390. [PubMed]

79. Dustman RE, Emmerson RY, Shearer DE. Life span changes in electrophysiological measures of inhibition. Brain and Cognition. 1996;30(1):109–126. [PubMed]
Connect with Get Your Boom! Back
Join the Get Your Boom! Back Movement
Learn the science 

Get Your Boom! Back Supplements

 P O Box 80267, Las Vegas, NV 89180| United States of America
Phone Australia: 1300 261 639 • UK: 01392 690 244 • USA: (225) 442-9766 • International +1 (225) 442-9766 
© Health Evolution LLC and Get Your Boom! Back 2020+

FDA Disclaimer

*These statements have not been evaluated by the Food and Drug Administration. These products and services are not intended to diagnose, treat, cure or prevent any disease.